Toward a harmonized assessment of MRD by NGS: blinded pilot study of NGS assays by MPAACT consortium
{{output}}
Background: Measurable residual disease (MRD) is a key prognostic factor in acute myeloid leukemia (AML). The Measurable residual disease Partnership and Alliance in Acute Myeloid Leukemia Clinical Treatment (MPAACT) Consortium a... ...
